What one share of Arrivent Biopharma holds
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers.
Arrivent Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.69 |
|---|---|
| Cash and investments | $3.20 |
| Book value | $7.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$32.38 | — | — | — | −$55.80 |
| 2024 | — | −$2.56 | — | — | — | $7.64 |
| 2025 | — | −$4.32 | — | — | — | $7.24 |
Common questions about Arrivent Biopharma
How much does one share of Arrivent Biopharma earn?
Over the last 12 months, Arrivent Biopharma lost $3.69 for each share.
Does Arrivent Biopharma pay a dividend?
Arrivent Biopharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Arrivent Biopharma’s book value per share?
Arrivent Biopharma’s book value is $7.59 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Arrivent Biopharma have?
Each share of Arrivent Biopharma has $3.20 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.